Rashmi Chhabra, MD
Internal Medicine · Green Valley, AZNPI 1356350615
Payments from drug & device makers
Across 237 payments — averaging $35.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Novo Nordisk$990
- Amgen$978
- GSK$846
- AbbVie$465
- Abbott$337
- plus $3K from 29 others
What the payments were for
- Food & beverage$8,22798%
- Education$1872%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,701 |
| Novo Nordisk | 16 | $990 |
| Amgen | 44 | $978 |
| GSK | 30 | $846 |
| AbbVie | 6 | $465 |
| Abbott | 3 | $337 |
| Lilly USA, LLC | 13 | $313 |
| Sanofi-aventis U.S. LLC | 3 | $266 |
| Astellas Pharma US Inc | 8 | $214 |
| Boehringer Ingelheim | 12 | $211 |
| Radius Health, Inc. | 6 | $190 |
| Merck | 3 | $168 |
| Boston Scientific | 3 | $160 |
| Viatris Specialty LLC | 6 | $145 |
| Tesaro, Inc. | 1 | $125 |
| Pfizer | 3 | $124 |
| E.r. Squibb & Sons, L.L.C. | 1 | $121 |
| Novartis | 6 | $114 |
| Bard Peripheral Vascular, Inc. | 1 | $111 |
| Sumitomo Pharma America, Inc. | 4 | $98 |
| Angiodynamics, Inc. | 1 | $89 |
| Exact Sciences | 5 | $87 |
| Aimmune Therapeutics, Inc. | 1 | $82 |
| Kestra Medical Technology Services, Inc. | 1 | $80 |
| Johnson & Johnson | 5 | $74 |
| Mylan Specialty L.p. | 1 | $62 |
| Sanofi Pasteur Inc. | 3 | $60 |
| Edwards Lifesciences | 1 | $48 |
| Amarin Pharma, Inc. | 3 | $42 |
| Eisai Inc. | 1 | $23 |
| GE HealthCare | 1 | $22 |
| Almatica Pharma LLC | 1 | $19 |
| Bardy Diagnostics, Inc. | 1 | $19 |
| Nestle Healthcare Nutrition Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$489
- TRELEGY ELLIPTA$364
- RYBELSUS$354
- VERQUVO$277
- EVENITY$272
- SOLIQUA 100/33$261
- VRAYLAR$249
- AREXVY$247
- AIRSUPRA$247
- MitraClip$150
- ENSITE PRECISION$128
- BREZTRI AEROSPHERE$125
- FARXIGA$125
- TEZSPIRE$125
- ZEJULA$125
- FASENRA$125
- MOUNJARO$123
- Tymlos$122
- COBENFY$121
- Lutonix Drug Coated Balloon$111
How this compares
$8,414 in reported general payments places this provider in the 90th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProliaDenosumab | 49 | $87,536 |
| TrulicityDulaglutide | 26 | $41,127 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $40,946 |
| OzempicSemaglutide | 16 | $29,309 |
| RybelsusSemaglutide | 11 | $28,495 |
| EliquisApixaban | 25 | $27,398 |
| JardianceEmpagliflozin | 12 | $20,461 |
| MyrbetriqMirabegron | 18 | $15,997 |
| GemtesaVibegron | 12 | $11,512 |
| Omeprazole | 216 | $6,076 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 35 | $4,074 |
| Levothyroxine Sodium | 460 | $4,058 |
| SynthroidLevothyroxine Sodium | 52 | $3,977 |
| Rosuvastatin Calcium | 287 | $3,069 |
| Metoprolol Succinate | 268 | $2,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenProlia | $978 | $87,53649 claims |
| Novo NordiskOzempic, Rybelsus | $990 | $57,80427 claims |
| Lilly USA, LLCTrulicity | $313 | $41,12726 claims |
| GSKTrelegy Ellipta | $846 | $40,94640 claims |
| PfizerEliquis | $124 | $27,39825 claims |
| Boehringer IngelheimJardiance | $211 | $20,46112 claims |
| Astellas Pharma US IncMyrbetriq | $214 | $15,99718 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $98 | $11,51212 claims |
| AbbVieSynthroid | $465 | $3,97752 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Green Valley
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.